Bone Metastasis – Pipeline Review, 2019

Bone is a common site for metastasis. Bone metastasis arises when cancer cells from the primary tumor relocate to the bone. Prostate, breast, and lung cancers are most likely to spread to the bone. Pain is the most common symptom that has been noticed by the patients. Pain is most often felt at the site of the metastasis, which is referred to as localized pain.

Current treatments for bone metastasis include medications, radiation therapy, and surgery. Medications used in people with bone metastasis include bone-building medications, chemotherapy, hormone therapy, pain medications, steroids, and targeted therapy. For instance, breast cancer cells that are HER2 positive respond to trastuzumab (Herceptin) therapy.

Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of bone metastasis. For instance; I-131-1095, which is being studied by the Progenics Pharmaceuticals, Inc., is currently in phase-2 clinical trials for the study of I-131-1095 radiotherapy in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Currently, more than 50% of the pipeline candidates for bone metastasis are in phase 2 and phase 3 stage. Majority of the studies have been sponsored by research institutes.

Report Description

The report on ‘Bone Metastasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for bone metastasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for bone metastasis.

The report on ‘Bone Metastasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.

Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for bone metastasis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for bone metastasis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary